LOUD CLAIMS.
REAL VERDICTS.

“BPC-157 cures everything — tendons, gut, nerves, brain, even depression.

BPC-157 shows remarkably broad tissue-protective effects in animal models — across tendon, gut, nerve, and vasculature. The "cures everything" framing overstates it. Human data is thin (a handful of small uncontrolled pilots), mechanism is plausible (NO modulation, VEGF signaling), and animal effects are reproducible. Broad animal data ≠ proven human clinical benefit for any single indication.

“BPC-157 heals broken bones twice as fast.

Rodent fracture models show accelerated healing with BPC-157. The "twice as fast" specific number comes from isolated animal findings, not human trials. There are no controlled human fracture studies. Plausible mechanism via VEGF + angiogenesis in healing tissue. Treat the claim as directionally interesting, not quantitatively proven.

“The BPC-157 + TB-500 "Wolverine Stack" is the best recovery combo in existence.

The mechanistic case is coherent — BPC-157 works locally via NO/VEGF signaling while TB-500 works systemically via actin sequestration. "Best in existence" is unprovable — no head-to-head trials exist against other recovery protocols (even against basic GHRP/GHRH stacks or standard physiotherapy). Community consensus is strong but the claim is inflated beyond what data supports.

“KPV cures inflammatory bowel disease orally.

Oral KPV reduces DSS-induced colitis severity by ~60% in rodent IBD models, and small human IBD biopsy cultures show reduced cytokine production. "Cures" goes too far — there are no completed controlled human IBD trials. It's a plausible complementary tool, not a monotherapy cure.

“You lose all your gains on GLP-1s.

The default outcome is ~25–40% of weight lost comes from lean mass — but that's not "all your gains" and it's not inevitable. Studies where patients hit 1.6–2.2g/kg protein and train with resistance 3x/week preserve ~90% of lean mass. Muscle loss on GLP-1s is a protein-intake and training-stimulus problem, not a drug-mechanism problem. Fix the inputs and you keep most of your muscle.

“Oral semaglutide is a scam — it barely works.

Oral sema (Rybelsus) has ~1% bioavailability and requires fasting. Effect size is real but meaningfully lower than injected semaglutide at comparable dosing. Calling it a "scam" is wrong — PIONEER trials showed legitimate HbA1c and weight effects. "Less efficient than injected" is accurate. Upcoming orforglipron (different small-molecule mechanism) is expected to be a real oral option.

“Retatrutide is the most powerful weight-loss drug ever developed.

April 2026 TRIUMPH Phase 3 data: 28.7% mean weight loss at 48 weeks, 12mg weekly — the highest figure ever recorded in a Phase 3 obesity trial. Exceeds tirzepatide (22.5%) and semaglutide (~15%) head-to-head on effect size. Triple-agonism (GLP-1 + GIP + glucagon) is what makes it stronger. Pending approval, this is the current ceiling.

“Compounded semaglutide is the exact same thing as Ozempic.

Same active molecule, yes. Same manufacturing oversight, no. Branded Ozempic/Wegovy is produced under FDA-mandated quality controls. Compounded versions come from 503A/B pharmacies (during shortages only) with variable QC — some are essentially identical, some have purity and potency issues. Third-party testing in 2024 found 5–20% of compounded semaglutide batches below label potency. "Same molecule" is true; "same product" is misleading.

“AOD-9604 melts fat with no side effects.

The one published human Phase 2b trial (n=534) showed just ~1.3 kg weight loss vs. placebo over 12 weeks — statistically significant but clinically underwhelming. "Melts fat" overstates it. "No side effects" is usually also too clean — injection reactions and mild GI are reported. AOD-9604 is a modest, clean lipolytic — not a miracle.

“Follistatin-344 turns you into a Belgian Blue bull.

Belgian Blues have a congenital myostatin null mutation present since birth affecting development. Injecting exogenous follistatin in a trained adult human doesn't replicate that at all. Animal follistatin studies show real hypertrophy, but the footage you see online with mice is misleading — adult humans on training plateaus won't see anything close to those effects. Gains are modest at best, cardiac hypertrophy concerns are real.

“CJC-1295 with DAC is better than CJC-1295 without DAC.

Backwards. For GH-pulse stacks (combined with ghrelin mimetics like Ipamorelin), no-DAC is preferred because GH is meant to be pulsatile. Sustained GHRH elevation from DAC leads to receptor downregulation and defeats the physiological pulse pattern. DAC form has niche use cases but isn't "better" as a general statement — it's a different drug for a different goal.

“Tesamorelin only works for HIV patients.

FDA-approved indication is HIV-associated lipodystrophy, but the mechanism (GHRH agonism → physiological GH pulses → VAT reduction) is completely agnostic to HIV status. Off-label use in non-HIV adults shows the same 15–18% visceral fat reduction at 2mg daily. "Only works for HIV" confuses FDA labeling with pharmacology.

“MK-677 gives you free gains with no downsides.

MK-677 (ibutamoren) is a ghrelin agonist. "Gains" are modest — mostly water retention, increased appetite-driven weight, some lean mass gain if training hard. Downsides include insulin resistance, elevated fasting glucose, water retention, elevated cortisol, and sleep architecture changes. Chronic sustained GH elevation via MK-677 is different from physiological GH pulses and carries its own risks.

“Epithalon extends human lifespan by 30%.

The 30% figure traces back to retrospective observational studies from Khavinson's Russian group in elderly cohorts. There are no controlled human lifespan trials (and there can't really be — the sample size and duration make it impossible). Animal data is interesting (telomerase activation) but doesn't cleanly translate to human longevity. Treat any specific lifespan-extension number as speculative.

“MOTS-c is literally exercise in a pill.

MOTS-c activates AMPK and produces exercise-like mitochondrial biogenesis signals in animal models. That doesn't make it "exercise in a pill" — exercise also produces cardiovascular conditioning, neurogenesis, bone density stimulus, blood pressure adaptation, mood effects via BDNF, and dozens of other effects MOTS-c doesn't replicate. Partial metabolic mimicry ≠ full exercise substitute.

“SS-31 reverses aging.

SS-31 (elamipretide) restores mitochondrial function in aged or damaged cells by binding cardiolipin. That's legitimately impressive and Phase 3 trials for Barth syndrome are progressing. "Reverses aging" is hype. Aging is not a single mitochondrial problem — telomere attrition, senescence, proteostasis loss, epigenetic drift, and stem cell exhaustion are all separate axes SS-31 doesn't touch. It's one piece of a much bigger puzzle.

“Semax gives you the Limitless-pill effect.

Semax has decades of Russian clinical use for cognitive enhancement post-stroke and for neuroprotection. Real effect: modest focus improvement, slight working memory enhancement, anxiolysis. "Limitless-pill" (NZT-48-grade cognition upgrade) is fantasy — no compound produces that effect. Semax is a solid research-backed nootropic, not a superpower.

“GHK-Cu regrows bald spots.

GHK-Cu shows hair-follicle-supportive effects — improved follicle size, anagen phase extension, reduced inflammation around follicles in studies. "Regrows bald spots" depends on what's bald: early thinning from miniaturization has more response than long-standing androgenic alopecia where follicles have died. It's supportive, not a reversal agent for late-stage male-pattern baldness.

“All research peptides are illegal in the US.

Mixed. Some peptides are on the FDA's Category 2 list (BPC-157, TB-500, thymosin alpha-1, and others) which means compounding pharmacies can't produce them — but buying from research-chemical suppliers labeled "for research use only" remains in a legal gray zone that varies by state. Other peptides have no such restrictions. And FDA-approved peptides (sema, tirz, tesamorelin, PT-141) are prescription-legal. "All illegal" is wrong; "simple and clear" also wrong.

“Peptides show up on employer drug tests.

Standard employment drug panels (the SAMHSA-5, 10-panel, or 12-panel tests) screen for common drugs of abuse — amphetamines, benzos, opioids, cannabinoids, PCP, cocaine, etc. They don't test for peptides. Peptides ARE detectable on sport-specific anti-doping panels (WADA-compliant testing at IOC, IFBB, NCAA, etc.) because WADA specifically adds assays for compounds like GH, GHRPs, and EPO. If you're not a competitive athlete, your employer isn't catching peptides.